IPO

News

Cancer Research UK spinout Achilles raises $175.5m in IPO

UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised T cell therapy for lung and ski

News

Protein misfolding specialist Gain nets $40m from IPO

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with prot

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Rubius launches $200m IPO to fund red blood cell therapies

Rubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel cell therapies targeting cancer and autoimmune diseases.

News

The rise and rise of digital health investment

UK biotech investment at record levels amid COVID-19

New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last year, with investment levels soaring to £2.8 billion ($3.8 billion) from a l

News

AI drug discovery biotech AbCellera eyes record IPO

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial publ

News

UK biotech sector sets new record with more than £1bn invest...

There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter.

Cancer Research UK spinout Achilles raises $175.5m in IPO

Protein misfolding specialist Gain nets $40m from IPO

Rubius launches $200m IPO to fund red blood cell therapies

UK biotech investment at record levels amid COVID-19

AI drug discovery biotech AbCellera eyes record IPO

UK biotech sector sets new record with more than £1bn invest...

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

How to meet your physicians where they are online

IPO

Editor's Picks